129 related articles for article (PubMed ID: 3954731)
1. Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators.
Kontoghiorghes GJ
Biochem J; 1986 Jan; 233(1):299-302. PubMed ID: 3954731
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators.
Kontoghiorghes GJ; Chambers S; Hoffbrand AV
Biochem J; 1987 Jan; 241(1):87-92. PubMed ID: 3566714
[TBL] [Abstract][Full Text] [Related]
3. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
Anderson D; Yardley-Jones A; Vives-Bauza C; Chua-Anusorn W; Cole C; Webb J
Teratog Carcinog Mutagen; 2000; 20(5):251-64. PubMed ID: 10992272
[TBL] [Abstract][Full Text] [Related]
4. 2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation.
Kontoghiorghes GJ
Biochim Biophys Acta; 1987 Apr; 924(1):13-8. PubMed ID: 3828392
[TBL] [Abstract][Full Text] [Related]
5. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
6. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
Brock JH; Licéaga J; Arthur HM; Kontoghiorghes GJ
Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
[TBL] [Abstract][Full Text] [Related]
7. Release of iron from ferritin molecules and their iron-cores by 3-hydroxypyridinone chelators in vitro.
Brady MC; Lilley KS; Treffry A; Harrison PM; Hider RC; Taylor PD
J Inorg Biochem; 1989 Jan; 35(1):9-22. PubMed ID: 2709002
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
Kontoghiorghes GJ
Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
[TBL] [Abstract][Full Text] [Related]
9. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators.
Longueville A; Crichton RR
Biochem Pharmacol; 1986 Nov; 35(21):3669-78. PubMed ID: 3778498
[TBL] [Abstract][Full Text] [Related]
10. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Florence A; Ward RJ; Peters TJ; Crichton RR
Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
[TBL] [Abstract][Full Text] [Related]
11. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
12. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.
Vlachodimitropoulou E; Chen YL; Garbowski M; Koonyosying P; Psaila B; Sola-Visner M; Cooper N; Hider R; Porter J
Blood; 2017 Oct; 130(17):1923-1933. PubMed ID: 28864815
[TBL] [Abstract][Full Text] [Related]
14. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Ballas S; Steinberg MH; Rigano P; Sacco M; Telfer P; Renda D; Barone R; Maggio A;
Blood Cells Mol Dis; 2014 Dec; 53(4):265-71. PubMed ID: 24814618
[TBL] [Abstract][Full Text] [Related]
15. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Emara AM; El Kelany RS; Moustafa KA
Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
[TBL] [Abstract][Full Text] [Related]
17. Iron release from haemosiderin and ferritin by therapeutic and physiological chelators.
O'Connell MJ; Ward RJ; Baum H; Peters TJ
Biochem J; 1989 Jun; 260(3):903-7. PubMed ID: 2764911
[TBL] [Abstract][Full Text] [Related]
18. Iron mobilization from ferritin by chelating agents.
Crichton RR; Roman F; Roland F
J Inorg Biochem; 1980 Dec; 13(4):305-16. PubMed ID: 7193239
[TBL] [Abstract][Full Text] [Related]
19. New orally active iron chelators.
Kontoghiorghes GJ
Lancet; 1985 Apr; 1(8432):817. PubMed ID: 2858689
[No Abstract] [Full Text] [Related]
20. Effect Comparison of Both Iron Chelators on Outcomes, Iron Deposit, and Iron Transporters After Intracerebral Hemorrhage in Rats.
Wang G; Hu W; Tang Q; Wang L; Sun XG; Chen Y; Yin Y; Xue F; Sun Z
Mol Neurobiol; 2016 Aug; 53(6):3576-3585. PubMed ID: 26099311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
